124 related articles for article (PubMed ID: 8522689)
21. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy.
Gawaz M; Neumann FJ; Ott I; May A; Schömig A
Circulation; 1996 Aug; 94(3):279-85. PubMed ID: 8759067
[TBL] [Abstract][Full Text] [Related]
22. Guidance of anticoagulation after intracoronary implantation of Palmaz-Schatz stents by monitoring prothrombin and prothrombin fragment 1 + 2.
Haude M; Hafner G; Jablonka A; Rupprecht HJ; Prellwitz W; Meyer J; Erbel R
Am Heart J; 1995 Aug; 130(2):228-38. PubMed ID: 7631600
[TBL] [Abstract][Full Text] [Related]
23. [The short-term results and angiographic predictors of subacute thrombosis in the coronary implantation of the Palmaz-Schatz endoprosthesis].
Díaz L; Fajadet J; Cassagneau B; Robert G; Marco J
Rev Esp Cardiol; 1994 Nov; 47(11):747-53. PubMed ID: 7800905
[TBL] [Abstract][Full Text] [Related]
24. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A case-control study.
Huczek Z; Filipiak KJ; Kochman J; Michalak M; Roik M; Piatkowski R; Grabowski M; Postula M; Opolski G
Thromb Res; 2010 May; 125(5):406-12. PubMed ID: 19786298
[TBL] [Abstract][Full Text] [Related]
25. Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
Moussa I; Di Mario C; Reimers B; Akiyama T; Tobis J; Colombo A
J Am Coll Cardiol; 1997 Jan; 29(1):6-12. PubMed ID: 8996288
[TBL] [Abstract][Full Text] [Related]
26. Stent thrombosis: incidence and related factors in the R.I.S.E. Registry(Registro Impianto Stent Endocoronarico).
De Servi S; Repetto S; Klugmann S; Bossi I; Colombo A; Piva R; Giommi L; Bartorelli A; Fontanelli A; Mariani G; Klersy C
Catheter Cardiovasc Interv; 1999 Jan; 46(1):13-8. PubMed ID: 10348558
[TBL] [Abstract][Full Text] [Related]
27. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents.
Haude M; Erbel R; Issa H; Straub U; Rupprecht HJ; Treese N; Meyer J
Am Heart J; 1993 Jul; 126(1):15-22. PubMed ID: 8322658
[TBL] [Abstract][Full Text] [Related]
28. Course of thrombin activation markers in patients implanted with Palmaz-Schatz stents: first experiences with a post-interventional anticoagulation regimen.
Haushofer A; Halbmayer WM; Dittel M; Prachar H; Mlczoch J; Fischer M
Blood Coagul Fibrinolysis; 1994 Oct; 5(5):697-706. PubMed ID: 7865675
[TBL] [Abstract][Full Text] [Related]
29. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial.
Schühlen H; Hadamitzky M; Walter H; Ulm K; Schömig A
Circulation; 1997 Apr; 95(8):2015-21. PubMed ID: 9133509
[TBL] [Abstract][Full Text] [Related]
30. [Subacute thrombosis with antiplatelet treatment in a non-selected population of intracoronary stents: incidence and predictors].
Pascual Figal DA; Valdés Chávarri M; Ruipérez JA; Cortés R; López Pálop R; Picó Aracil F; García Alberola A
Rev Esp Cardiol; 2000 Jun; 53(6):791-6. PubMed ID: 10944971
[TBL] [Abstract][Full Text] [Related]
31. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis.
Walter DH; Schächinger V; Elsner M; Dimmeler S; Zeiher AM
Lancet; 1997 Oct; 350(9086):1217-9. PubMed ID: 9652563
[TBL] [Abstract][Full Text] [Related]
32. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis.
Knight CJ; Panesar M; Wilson DJ; Patrineli A; Chronos N; Wright C; Clarke D; Patel D; Fox K; Goodall AH
Eur Heart J; 1998 Aug; 19(8):1239-48. PubMed ID: 9740346
[TBL] [Abstract][Full Text] [Related]
33. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model.
Beythien C; Gutensohn K; Bau J; Hamm CW; Kühnl P; Meinertz T; Terres W
Thromb Res; 1999 Apr; 94(2):79-86. PubMed ID: 10230892
[TBL] [Abstract][Full Text] [Related]
34. Polymorphism of platelet glycoprotein IIb and risk of thrombosis and restenosis after coronary stent placement.
Böttiger C; Kastrati A; Koch W; Mehilli J; von Beckerath N; Dirschinger J; Gawaz M; Schömig A
Am J Cardiol; 1999 Nov; 84(9):987-91. PubMed ID: 10569651
[TBL] [Abstract][Full Text] [Related]
35. Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.
Nath FC; Muller DW; Ellis SG; Rosenschein U; Chapekis A; Quain L; Zimmerman C; Topol EJ
J Am Coll Cardiol; 1993 Mar; 21(3):622-7. PubMed ID: 8436743
[TBL] [Abstract][Full Text] [Related]
36. [Animal experimental studies on the effect of flow restriction on the thrombogenicity of the Palmaz stent using 111Indium-marked thrombocytes].
Nöldge G; Richter GM; Siegerstetter V; Garcia O; Palmaz JC
Rofo; 1990 Mar; 152(3):264-70. PubMed ID: 2157247
[TBL] [Abstract][Full Text] [Related]
37. Coronary artery stents: appropriate use of adjunctive pharmacotherapy to prevent stent thrombosis.
Gruberg L; Dangas G; Leon MB
Drugs Aging; 1999 Nov; 15(5):341-8. PubMed ID: 10600042
[TBL] [Abstract][Full Text] [Related]
38. Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen.
Ochiai M; Isshiki T; Takeshita S; Eto K; Toyoizumi H; Sato T; Miyashita H
Am J Cardiol; 1997 Jun; 79(11):1471-4. PubMed ID: 9185635
[TBL] [Abstract][Full Text] [Related]
39. In vitro model to test the thrombogenicity of coronary stents.
Beythien C; Terres W; Hamm CW
Thromb Res; 1994 Sep; 75(6):581-90. PubMed ID: 7831677
[TBL] [Abstract][Full Text] [Related]
40. [Changes and significance of P-selectin and PAC-1 in coronary heart disease before and after stenting].
Hou M; Yu J; Zhang L; Liu C
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):766-8. PubMed ID: 24844962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
